查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971771

感染疾病治療市場分析及預測（至2035年）：依類型、產品、服務、技術、應用、最終使用者、設備、流程及解決方案分類

Infectious Disease Therapeutics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Process, Solutions
出版日期: | 出版商: Global Insight Services | 英文 425 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計感染疾病治療市場規模將從2024年的1,267億美元成長到2034年的1,930億美元，複合年成長率約為4.3%。該市場涵蓋病毒、細菌、真菌和寄生蟲性行為感染的治療，包括抗生素、抗病毒藥物、抗真菌藥物和疫苗，並專注於新藥研發和抗抗藥性措施。感染疾病上升、研發投入增加以及生物技術的進步正在推動市場成長。公眾意識的提高、政府主導的各項舉措，以及對個人化醫療和快速診斷的重視（旨在提高治療效果和改善患者預後），進一步刺激了市場需求。

受藥物研發進展和感染疾病上升的推動，感染疾病治療市場正經歷強勁成長。其中，抗病毒療法特別突出，愛滋病和肝炎治療領域的創新是主要驅動力。抗菌療法緊隨其後，重點在於對抗抗藥性細菌。疫苗是關鍵成長領域，針對新興感染疾病的新型疫苗備受關注。單株抗體正成為極具發展潛力的細分市場，提供副作用較少的標靶治療選擇。抗真菌藥物真菌療法也呈現成長勢頭，旨在應對免疫力缺乏患者中真菌感染疾病日益增多的問題。新型藥物遞送系統的研發正在提高治療藥物的療效和可近性。生物製藥和生物相似藥透過提供經濟有效的替代方案，為市場擴張做出貢獻。人工智慧在藥物研發和個人化醫療的應用有望變革治療方法，最佳化治療效果，並推動未來的成長。

市場區隔
類型 抗菌劑、抗病毒藥物、抗真菌劑、抗寄生蟲劑、疫苗、免疫調節劑、生物製藥、小分子化合物
產品 口服藥物、注射藥物、外用製劑、吸入藥物、靜脈注射藥物、經皮貼片
服務 臨床試驗、法規遵循、契約製造、藥物研發
科技 基因組學、蛋白質組學、代謝體學、奈米技術、CRISPR
目的 愛滋病毒、肝炎、流感、結核病、瘧疾、新冠肺炎、醫院感染
最終用戶 醫院、診所、研究機構、製藥公司、生技公司
裝置 診斷設備、輸液設備、監測設備
過程 藥物發現、非臨床試驗、臨床試驗、核准、商業化
解決方案 感染控制、合理使用抗生素方案、快速診斷

市場概況：

感染疾病治療市場的特徵是市場佔有率、定價策略和新產品上市之間存在著動態的相互作用。製藥公司正利用先進技術推出創新療法，以提高療效並改善患者預後。醫療政策和報銷框架加劇了定價策略的競爭。研發投入的增加以及致力於滿足未被滿足的醫療需求的努力，推動了市場上新產品的湧現。旨在拓展市場和強化產品系列的策略聯盟和併購進一步塑造了這個不斷變化的市場格局。傳染病治療市場的競爭異常激烈，主要企業專注於透過創新和策略聯盟實現差異化。監管影響顯著，嚴格的核准流程影響產品上市的速度。北美和歐洲憑藉其強大的感染疾病基礎設施和有利的法規環境。亞太地區正崛起為一個高盈利市場，這主要得益於投資的增加和感染疾病的蔓延。生物技術和個人化醫療的進步創造了充滿希望的前景，市場正蓄勢待發，成長勢頭強勁。

主要趨勢和促進因素：

感染疾病治療市場正經歷強勁成長，這主要得益於幾個關鍵趨勢和促進因素。其中一個顯著趨勢是，為應對新出現的感染疾病和流行病，研發活動激增，旨在發現新的療法和疫苗。生物技術和基因組學的進步正在加速個人化醫療的發展，提供更有針對性和更有效的治療方法。另一個趨勢是製藥公司與研究機構之間合作的加強，這加速了藥物發現過程，並促進了創新治療方法的開發。世界各國政府對醫療基礎設施的大量投資進一步推動了市場成長。法規結構也不斷完善，以加速新藥核准，確保患者及時獲得救命療法。市場促進因素包括需要有效治療方案的感染疾病在全球範圍內的不斷蔓延。人們意識的提高和診斷能力的增強也推動了對先進治療方法的需求。此外，發展中地區醫療服務覆蓋範圍的擴大也創造了新的機會。能夠妥善應對監管環境並投資於前沿研發的公司，將更有利於利用這些趨勢和促進因素，確保市場永續成長。

壓制與挑戰：

感染疾病治療市場面臨許多重大限制與挑戰。其中一個突出障礙是藥物研發高成本，這對許多公司，尤其是中小企業而言，構成了沉重的財務負擔。這種財務負擔往往限制了研發活動，減緩了創新步伐。此外，嚴格的監管要求會延誤核准流程，進一步加重財務負擔，並延長新治療方法的上市時間。抗藥性病原體的出現也使治療通訊協定複雜化，需要持續的研究和調整。此外，醫療基礎設施的差異限制了藥物的分發和供應，使得確保不同地區患者公平獲得治療成為一項持續的挑戰。最後，諸如大流行病等公共衛生突發事件會分散資源和注意力，使其他感染疾病的研發工作受到影響。這些因素共同阻礙了市場成長和藥物可近性，需要製定策略解決方案來克服這些挑戰。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 抗菌劑
    • 抗病毒藥物
    • 抗真菌劑
    • 抗寄生蟲藥物
    • 疫苗
    • 免疫調節劑
    • 生物製藥
    • 低分子化合物
  • 市場規模及預測：依產品分類
    • 口服藥物
    • 注射藥物
    • 外用製劑
    • 吸入製劑
    • 靜脈注射藥物
    • 經皮吸收貼劑
  • 市場規模及預測：依服務分類
    • 臨床試驗
    • 監理合規
    • 契約製造
    • 藥物研發
  • 市場規模及預測：依技術分類
    • 基因組學
    • 蛋白質體學
    • 代謝體學
    • 奈米科技
    • CRISPR
  • 市場規模及預測：依應用領域分類
    • HIV
    • 肝炎
    • 流感
    • 結核
    • 瘧疾
    • COVID-19
    • 院內感染
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究機構
    • 製藥公司
    • 生技公司
  • 市場規模及預測：依設備分類
    • 診斷設備
    • 藥物輸送裝置
    • 監控設備
  • 市場規模及預測：依製程分類
    • 藥物發現
    • 非臨床試驗
    • 臨床試驗
    • 核准
    • 商業化
  • 市場規模及預測：按解決方案分類
    • 感染控制
    • 合理使用抗生素
    • 快速診斷

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Gilead Sciences
  • Regeneron Pharmaceuticals
  • BioCryst Pharmaceuticals
  • Arcturus Therapeutics
  • Vir Biotechnology
  • Novavax
  • Spero Therapeutics
  • Atea Pharmaceuticals
  • Vaxart
  • Dynavax Technologies
  • Inovio Pharmaceuticals
  • Iovance Biotherapeutics
  • Moderna
  • Valneva
  • CureVac
  • Bavarian Nordic
  • Sorrento Therapeutics
  • Altimmune
  • Siga Technologies
  • Emergent BioSolutions

第9章 關於我們

簡介目錄
Product Code: GIS33151

Infectious Disease Therapeutics Market is anticipated to expand from $126.7 billion in 2024 to $193.0 billion by 2034, growing at a CAGR of approximately 4.3%. The Infectious Disease Therapeutics Market encompasses treatments targeting viral, bacterial, fungal, and parasitic infections. It includes antibiotics, antivirals, antifungals, and vaccines, emphasizing novel drug development and resistance management. The market is propelled by rising infection rates, increased R&D investments, and advancements in biotechnology. Growing awareness and government initiatives further fuel demand, with a focus on personalized medicine and rapid diagnostics to enhance treatment efficacy and patient outcomes.

The Infectious Disease Therapeutics Market is experiencing robust growth, fueled by advancements in drug development and increasing prevalence of infectious diseases. The antiviral therapeutics segment leads in performance, particularly driven by innovations in HIV and hepatitis treatments. Antibacterial therapeutics follow closely, with a focus on combating antibiotic-resistant strains. Vaccines represent a significant growth area, with novel vaccines for emerging diseases gaining attention. Monoclonal antibodies are emerging as a promising sub-segment, offering targeted treatment options with fewer side effects. The antifungal segment is also gaining momentum, addressing rising incidences of fungal infections in immunocompromised patients. Research and development in novel drug delivery systems are enhancing the efficacy and accessibility of therapeutics. Biologics and biosimilars are contributing to market expansion, providing cost-effective alternatives. The integration of artificial intelligence in drug discovery and personalized medicine is poised to transform therapeutic approaches, optimizing treatment outcomes and driving future growth.

Market Segmentation
TypeAntibacterials, Antivirals, Antifungals, Antiparasitics, Vaccines, Immune Modulators, Biologics, Small Molecules
ProductOral Drugs, Injectable Drugs, Topical Formulations, Inhalation Formulations, Intravenous Drugs, Transdermal Patches
ServicesClinical Trials, Regulatory Compliance, Custom Manufacturing, Drug Development
TechnologyGenomics, Proteomics, Metabolomics, Nanotechnology, CRISPR
ApplicationHIV, Hepatitis, Influenza, Tuberculosis, Malaria, COVID-19, Hospital Acquired Infections
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies, Biotechnology Firms
DeviceDiagnostic Devices, Drug Delivery Devices, Monitoring Devices
ProcessDiscovery, Preclinical Trials, Clinical Trials, Approval, Commercialization
SolutionsInfection Control, Antimicrobial Stewardship, Rapid Diagnostics

Market Snapshot:

The Infectious Disease Therapeutics Market is characterized by a dynamic interplay of market share, pricing strategies, and new product launches. Pharmaceutical companies are leveraging advanced technologies to introduce innovative therapeutics, enhancing treatment efficacy and patient outcomes. Pricing strategies remain competitive, influenced by healthcare policies and reimbursement frameworks. The market is witnessing a surge in product launches, driven by increased R&D investments and a focus on addressing unmet medical needs. This evolving landscape is further shaped by strategic partnerships and mergers aimed at expanding market reach and enhancing product portfolios. Competition in the Infectious Disease Therapeutics Market is intense, with key players focusing on differentiation through innovation and strategic alliances. Regulatory influences are significant, with stringent approval processes impacting the speed of product launches. North America and Europe dominate the market, driven by robust healthcare infrastructures and supportive regulatory environments. Asia-Pacific is emerging as a lucrative region, fueled by growing investments and increasing prevalence of infectious diseases. The market is poised for growth, with advancements in biotechnology and personalized medicine offering promising prospects.

Geographical Overview:

The Infectious Disease Therapeutics Market is witnessing notable growth across various regions, each exhibiting unique dynamics. North America leads the market, driven by advanced healthcare infrastructure and significant R&D investments. The presence of key pharmaceutical companies further propels the market. Europe follows, with robust government initiatives and funding for infectious disease research bolstering market growth. Asia Pacific is experiencing rapid expansion, fueled by increasing healthcare expenditure and a rising prevalence of infectious diseases. Emerging economies like India and China are at the forefront, with substantial investments in healthcare innovation. Latin America presents new growth pockets, with improving healthcare systems and rising awareness about infectious disease treatment. The Middle East & Africa are also gaining traction, recognizing the critical need for effective therapeutics in combating infectious diseases. These regions are seeing increased collaborations with global pharmaceutical firms, which enhances their market potential and fosters innovation in therapeutics.

Key Trends and Drivers:

The Infectious Disease Therapeutics Market is experiencing robust growth, propelled by several key trends and drivers. One significant trend is the surge in research and development activities aimed at discovering novel therapeutics and vaccines. This is fueled by the urgent need to combat emerging infectious diseases and pandemics. Advances in biotechnology and genomics are facilitating the development of personalized medicine, offering targeted and effective treatments. Another trend is the increasing collaboration between pharmaceutical companies and research institutions. This collaboration accelerates the drug discovery process and enhances the development of innovative therapies. Governments worldwide are investing heavily in healthcare infrastructure, further boosting market growth. Regulatory frameworks are evolving to expedite the approval of new drugs, ensuring timely access to life-saving treatments. Market drivers include the rising prevalence of infectious diseases globally, necessitating effective therapeutic solutions. Growing awareness and improved diagnostic capabilities are also driving demand for advanced treatments. Additionally, the expansion of healthcare access in developing regions is creating new opportunities. Companies that can navigate regulatory landscapes and invest in cutting-edge research are poised to capitalize on these trends and drivers, ensuring sustained market growth.

Restraints and Challenges:

The infectious disease therapeutics market is confronted with several significant restraints and challenges. A prominent hurdle is the high cost of drug development, which poses financial barriers for many companies, particularly smaller firms. This financial burden often results in limited research and development activities, slowing innovation. Moreover, stringent regulatory requirements can delay the approval process, adding further financial strain and extending time-to-market for new therapies. The emergence of drug-resistant strains of pathogens also complicates treatment protocols, necessitating continuous research and adaptation. Additionally, there is a persistent challenge in ensuring equitable access to therapies across different regions, as disparities in healthcare infrastructure can limit distribution and availability. Lastly, public health emergencies, such as pandemics, can redirect resources and attention away from other infectious diseases, impacting ongoing research and development efforts. These factors collectively impede the market's growth and accessibility, requiring strategic solutions to overcome them.

Key Players:

Gilead Sciences, Regeneron Pharmaceuticals, BioCryst Pharmaceuticals, Arcturus Therapeutics, Vir Biotechnology, Novavax, Spero Therapeutics, Atea Pharmaceuticals, Vaxart, Dynavax Technologies, Inovio Pharmaceuticals, Iovance Biotherapeutics, Moderna, Valneva, CureVac, Bavarian Nordic, Sorrento Therapeutics, Altimmune, Siga Technologies, Emergent BioSolutions

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Antibacterials
    • 4.1.2 Antivirals
    • 4.1.3 Antifungals
    • 4.1.4 Antiparasitics
    • 4.1.5 Vaccines
    • 4.1.6 Immune Modulators
    • 4.1.7 Biologics
    • 4.1.8 Small Molecules
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Oral Drugs
    • 4.2.2 Injectable Drugs
    • 4.2.3 Topical Formulations
    • 4.2.4 Inhalation Formulations
    • 4.2.5 Intravenous Drugs
    • 4.2.6 Transdermal Patches
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Clinical Trials
    • 4.3.2 Regulatory Compliance
    • 4.3.3 Custom Manufacturing
    • 4.3.4 Drug Development
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Genomics
    • 4.4.2 Proteomics
    • 4.4.3 Metabolomics
    • 4.4.4 Nanotechnology
    • 4.4.5 CRISPR
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 HIV
    • 4.5.2 Hepatitis
    • 4.5.3 Influenza
    • 4.5.4 Tuberculosis
    • 4.5.5 Malaria
    • 4.5.6 COVID-19
    • 4.5.7 Hospital Acquired Infections
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Biotechnology Firms
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Diagnostic Devices
    • 4.7.2 Drug Delivery Devices
    • 4.7.3 Monitoring Devices
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Discovery
    • 4.8.2 Preclinical Trials
    • 4.8.3 Clinical Trials
    • 4.8.4 Approval
    • 4.8.5 Commercialization
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Infection Control
    • 4.9.2 Antimicrobial Stewardship
    • 4.9.3 Rapid Diagnostics

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Gilead Sciences
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Regeneron Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 BioCryst Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Arcturus Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Vir Biotechnology
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Novavax
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Spero Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Atea Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Vaxart
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Dynavax Technologies
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Inovio Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Iovance Biotherapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Moderna
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Valneva
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 CureVac
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Bavarian Nordic
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Sorrento Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Altimmune
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Siga Technologies
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Emergent BioSolutions
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us